The Hyperkalemia Drugs Market is expected to increase by USD 927.9 million billion. As per the research report 2024-2028 published by Technavio, the market is expected to grow at a CAGR of 20.62% during the forecast period. The industry is segmented by Type (Chronic hyperkalemia and Acute hyperkalemia) and Geography (North America, Europe, Asia, and Rest of World (ROW)).
The Hyperkalemia Drugs Market represents a significant business opportunity due to the rising prevalence of conditions leading to elevated potassium levels, such as kidney diseases and heart failure. Key players in this market include Relypsa, Sanofi, and AstraZeneca, who offer potassium-binding agents and other treatments to manage this potentially life-threatening condition. Market growth is driven by increasing disease awareness, diagnostic advancements, and the development of novel therapeutics.
Know what factors are driving the market growth - Access free sample report
The North America hold the largest regional market size in the current year. The Hyperkalemia Drugs Market represents a significant business opportunity due to the rising prevalence of conditions leading to elevated potassium levels, such as kidney diseases and diabetes. Key players in this market include Relypsa, AstraZeneca, and Sanofi, who offer potassium-binding agents and other treatments to manage hyperkalemia. Market growth is driven by increasing awareness and diagnostic advancements, as well as the development of novel therapeutic approaches.
Know which companies are participating in the market- Download the report
The global pharmaceuticals market encompasses entities involved in the research and development (R&D) or manufacturing of various pharmaceutical offerings, including generic drugs, non-generic drugs, and veterinary drugs. According to Technavio, the healthcare industry's overall market size is determined by the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the global pharmaceuticals market include the increasing aging population, with predictions suggesting that by 2050, approximately one-quarter of the US population and Europe's population by 2030 will be over 60 years old.
The Hyperkalemia Drugs Market is experiencing significant growth, fueled by the Growing cases of chronic diseases. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
The Hyperkalemia Drugs Market has witnessed significant growth in recent years due to the increasing prevalence of heart failure, cardiac arrest, metabolic and renal diseases, and cardiovascular diseases that can lead to elevated potassium levels in the blood. Companies like ZS Pharma, with their FDA-approved medication Lokelma, are at the forefront of this market. Lokelma is a potassium binder indicated for the treatment of hyperkalemia in various patient populations, including those with heart failure, renal diseases, and comorbidities. Other medications for hyperkalemia include those used for treating hypokalemia, such as potassium chloride. The adoption rates of these drugs are influenced by factors like patient assistance programs, customer purchase basket, and strategic alliances. Risk factors for hyperkalemia include congestive heart failure, chronic kidney disease, and aging population, leading to an increased number of emergency department visits and healthcare costs. The market for hyperkalemia drugs is expected to grow further due to the increasing burden of chronic hyperkalemia and electrolyte imbalances. AdvaCare International is another key player in this market, focusing on providing affordable treatment options for patients. The purchase criteria for these drugs include safety, efficacy, and cost-effectiveness.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
